SKYE SKYE BIOSCIENCE INC

Skye Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is based in San Diego, California.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$0.05    OTCQB
As of 01/27/2022     OTCMarkets


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Unknown
Industry:  
Index country:  USA
Country of incorporation:  
IPO date:  06/01/2021
Outstanding shares:  476,108,445
Average volume:  1,677,841
Market cap:   $22,234,264
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   2.76
PS ratio:   0.00
Return on equity:   -90.89%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy